There are three key elements to our business strategy:

1: Focus on developing novel, cell cycle-based therapies for the treatment of cancer and other serious disease indications.

2: Develop anticancer drug candidates in all phases of the cell cycle and multiple compounds for particular cell cycle targets.

Targeting a broad development program focused on multiple phases of the cell cycle allows Cyclacel to minimize risk while maximizing the potential for success and also to develop products that are complementary to one another.

3: Enter into partnering arrangements selectively, while developing our own sales and marketing capability.

Cyclacel retains all marketing rights to the compounds associated with the current clinical-stage drug programs. To optimize our commercial return, we intend to develop our sales and marketing capability to market the products ourselves and/or enter into selected partnering arrangements initially retaining co-promotion rights. Generally we develop compounds through the Phase 2 proof-of-efficacy stage before seeking a partner. We may be prepared to enter into partnering arrangements earlier in connection with drug programs outside the current oncology core competency.